Loading...
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) is standard front-line therapy for diffuse large B-cell lymphoma (DLBCL), but it fails to cure a third or more of patients. DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) is a pharmacodynamically adaptive infusional regimen that was shown to improve patient responses in earlier trials (e.g., NEJM JW Oncol Hematol Jul 2008 and J Clin Oncol 2008; 26:2717).
Now, investigators have conducted a multicenter, randomized, phase III study to compare R-CHOP versus DA-EPOCH-R in 491 eligible patients with newly diagnosed, stage II to IV DLBCL. A fresh tissue biopsy or frozen tissue was required to determine cell of…